Polycystic ovarian syndrome and insulin resistance: Implications for estrogen use in premenopausal and postmenopausal women

Metabolic Syndrome and Related Disorders

Volumn 3, Issue 3, 2005, Pages 259-269

  Cobin, Rhoda H ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PROGESTERONE;

AGING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE PREDISPOSITION; ESTROGEN THERAPY; FEMALE; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; MENOPAUSAL SYNDROME; MENSTRUATION DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; POSTMENOPAUSE; PREMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SYSTEMATIC REVIEW;

EID: 27744592695     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2005.3.259     Document Type: Review

References (76)

1. Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89:2745-2749.
2. Kent SC, Legro RS. Polycystic ovary syndrome in adolescents. Adolesc Med 2002;13:73-88,vi.
3. Winters SJ, Talbott E, Guzick DS, et al. Serum testosterone levels decrease in middle age in women with the polysyctic ovary syndrome, Fertil Steril 2000;73: 724-729.
4. Glueck CJ, Papanna P, Wang P. Incidence and treatment of the metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003;52:908-915.
5. Barontini M, Garcia-Rudaz MC, Veldhuis JD. Mechanisms of hypothalamic-pituitary-gonadal disruption in polycystic ovarian syndrome. Arch Med Res 2001; 32:544-552.
6. Rosenfield RL, Ehrmann DA, Barnes RB, et al. Gonadotropin-releasing hormone agonist as a probe for the pathogenesis and diagnosis of ovarian hyperandrogenism. Ann NY Acad Sci 1993;687:162-181.
7. Jakubowicz DJ, Nestler JE. 17-Alpha-hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss. J Clin Endocrinol Metab 1997;82:556-560.
8. La Marca A, Morgante G, Palumbo M, et al. Insulin-lowering treatment reduces aromatase activity in response to follicle-stimulating hormone in women with polycystic ovary syndrome Fertil Steril 2002;78: 1234-1239.
9. Guido M, Romualdi D, Suriano R, et al. Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome. Hum Reprod 2004;19:534-539.
10. Ortega-Gonzalez C, Cardoza L, Coutino B, et al. Insulin-sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. J Endocrinol 2005; 184:233-239.
11. Talbott EO, Zborowski JV, Boudreaux MY. Do women with polycystic ovary syndrome have an increased risk of cardiovascular disease? Review of the evidence. Minerva Ginecol 2004;56:27-39.
12. Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141-146.
13. Legro RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome; a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-169.
14. Palmert MR, Gordon CM, Kartashov AL, et al. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:1017-1023.
15. Peppard HR, Marfori J, Iuorno MJ, et al. Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. Diabetes Care 2001; 24:1050-1052.
16. Wild RA, Painter PC, Coulson PB, et al. Lipoprotein lipid concentration and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985;61:946-951.
17. Talbott EO, Clerici A, Berga SL, et al. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case control study. J Clin Epidemiol 1998;51:415-422.
18. Mather KJ, Kwan P, Corenblum B. Hyperinsulinemia in polycystic ovary syndrome correlated with increased cardiovascular risk independent of obesity. Fertil Steril 2000;73:150-156.
19. Holte J, Gennarelli G, Berne G, et al. Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a prehypertensive state? Hum Reprod 1996;11:23-28.
20. Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improved defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:2108-2116.
21. Kelly CCJ, Lyall H, Petrie JR, et al. Low-grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001; 86:2453-2455.
22. Boulman N, Levy Y, Leiba R, et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004;2160-2164.
23. Christian RC, Dumesic DA, Behrenbeck T, et al. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:2562-2568.
24. Talbott EO, Zborowski JV, Rager JR, et al. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:5454-5461.
25. Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for an association between polycystic ovary and premature carotid atherosclerosis in middle-aged women. Arterioscl Thromb Vasc Biol 2000;20:2414-2421.
26. Dahlgren E, Janson PO, Johansson S, et al. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992;71:599-604.
27. Cibula D, Cifkova R, Fanta M, et al. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary heart disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000;15:785-789.
28. Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and coronary heart disease risk in women having cardiac catheterization. Ann Intern Med 1997;126:32-35.
29. Solomon CG, Hu FB, Dunaif A, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002;87:2013-2017.
30. Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and coronary heart disease risk in women having cardiac catheterization. Ann Intern Med 1997;126:32-35.
31. Orio F, Palomba S, Spinelli L, et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:3696-3701.
32. Bruni V, Dei M, Pontello V, et al. The management of polycystic ovary syndrome. Ann N Y Acad Sci 2003; 997:307-321.
33. Nestler JE. Should patients with polycystic ovarian syndrome be treated with metformin?: an enthusiastic endorsement. Hum Reprod 2002;17:1950-1953.
34. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, et al. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:524-529.
35. Ibanez L, de Zegher F. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism have opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 2004;89: 1592-1597.
36. Knowler WC, Barrett-Connor E, Fowler SE. Reduction in incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
37. Azen SP, Peters RK, Berkowitz K. TRIPOD (TRoglitazone In the Prevention Of Diabetes); a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 1998;19:217-231.
38. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
39. Garcia-Arencibia M, Molero S, Davila N, et al. 17β-Estradiol transcriptionally represses human insulin receptor gene expression causing cellular insulin resistance. Leuk Res 2005;;29:79-87.
40. Xie P, Liu ML Gu YP, et al. Oestrogen improves glucose metabolism and insulin signal transduction in HepG2 cells. Clin Esp Pharmacol Phisiol 2003;3:643-648.
41. Huang SW, Seow KM, Ho LT, et al. Resistin mRNA levels are downregulated by estrogen in vivo and in vitro. FEBS Lett 2005;579:449-454.
42. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-1811.
43. Moorthy K, Yadav UC, Siddiqui MR, et al. Effect of estradiol and progesterone treatment on carbohydrate metabolizing enzymes in tissues of aging female rats. Biogerontology 2004;4:249-259.
44. Bruun JM, Nielsen CB, Pedersen SB, et al. Estrogen reduces pro-inflammatory cytokines in rodent adipose tissue: studies in vivo and in vitro, Horm Metab Res 2003;35:142-146.
45. Louet JF, LeMay C, Mauvais-Jarvis F. Antidabetic actions of estrogen: insight from human and genetic mouse models. Curr Atheroscler Rep 2004;6:180-185.
46. Pasquali R, Gambineri A, Anconetani B, et al. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol (Oxf) 1999;50:517-527.
47. Armstrong VL, Wiggam MI, Ennis CN, et al. Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate. QJM 2001;94:31-37.
48. Cagnacci A, Paoletti AM, Renzi A, et al. Glucose metabolism and insuslin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. J Clin Endocrinol Metab 2003;88:3621-3625.
49. Villaseca P, Hormaza P, Cardenas I, et al. Ethinylestradiol/cyproterone acetate in polycystic oavary syndrome: lipid and carbohydrate changes. Eur J Contracept Reprod Health Care 2004;9:155-165.
50. Vrbikova J, Stanicka S, Dvorakova K, et al. Metabolic and endocrine effects of treatment with peroral or transdermal oestrogens in conjunction with peroral cyproterone acetate in women with polycystic ovary syndrome. Eur J Endocrinol 2004;150:215-223.
51. Ibanez L, de Zegher F. Ethinylesradiol-drosperirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 2004;89:1592-1597.
52. Morin-Papunen L, Vauhkonen I, Koivenen R, et al. Metformin versus ethinyl estradio-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2003;88:148-156.
53. Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-syproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod 2002;17:1729-1737.
54. Mitkov M, Pehlivanov B, Terzieva D. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2005;118:209-213.
55. Cibula D, Fanta M, Vrbikova J, et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Hum Reprod 2005;20:180-184.
56. Rechberger T, Tomaszewski J, Pieprzowska-Bialek A, et al. Serum resistin levels in women taking combined oral contraceptives containing desogestrel or gestodene. Contraception 2004;69:477-480.
57. Krotkiewski M, Landin K, Dahlgren E, et al. Effect of two modes of antiandrogen treatment on insulin sensitivity and serum leptin in women with PCOS. Gynecol Obstet Invest 2003;55:88-95.
58. Morin-Papunen L, Rautio K, Ruokonen A, et al. Metformin reduces serum C-reative protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:4649-4654.
59. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003;88: 2404-2411.
60. Sowers M, Derby C, Jannausch ML, et al. Insulin resistance, hemostatic factors and hormone interactions in pre- and perimenopausal women: SWAN. J Clin Endocrinol Metab 2003;8;4904-4910.
61. Kalish GM, Barrett-Conner E, Laughlin GA, et al. Postmenopausal Estrogen/Progestin Intervention Trial. Association of endogenous sex hormones and insulin resistance among postmenopausal women: results from the Postmenopausal Estrogen/Progestin Intervention Trial. J Clin Endocrinol Metab 2003;88: 1646-1652.
62. Zarate A, Basurto L, Hernandez M. The metabolic syndrome in postmenopausal women. Gac Med Mex 2003;139:625-628.
63. Rosano GM, Vitale C, Silvestri A, et al. Metabolic and vascular effect of progestins in post-menopausal women. Implication for cardioprotection. Maturitas 2003;46:S17-S29.
64. Andersson B, Mattsson A, Hahn L, et al. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metabol 1997;82: 638-643.
65. Brussaard H, Gevers Leuven JA, Frölich M, et al. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia 1997; 40:843-849.
66. Sites CK, Broschu M, Tchernof A, et al. Relationship between hormone replacement therapy use with body fat distribution and insulin sensitivity in obese postmenopausal women. Metabolism 2001;50:835-840.
67. Assali AR, Jabara Z, Shafer Z, et al. Insulin resistance is increased by transdermal estrogen therapy in postmenopausal women with cardia syndrome X. Cardiology 2001;95:31-34.
68. Munoz J, Derstine A, Gower BA. Fat distribution and insulin sensitivity in postmenopausal women: influence of hormone replacement. Obes Res 2002;10:424-431.
69. Saglam K, Polat Z, Yilmaz MI, et al. Effects of postmenopausal hormone replacement therapy on insulin resistance. Endocrine 2002;18:211-214.
70. Sumino H, Ichikawa S, Itoh H, et al. Hormone replacement therapy decreases insulin resistance and lipid metabolism in Japanese postmenopausal women with impaired glucose tolerance. Horm Res 2003; 60:134-142.
71. Green JS, Stanforth PR, Rankinen T, et al. The effects of exercise training on abdominal visceral fat, body compaosition and indicator of the metabolic syndrome in postmenopausal women with and without estrogen replacement therapy: the HERITAGE family study. Metabolism 2004;53:1192-1196.
72. McKenzie J, Jaap AJ, Gallacher S, et al. Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk? Clin Endocrinol (Oxf) 2003;59:682-689.
73. Godsland IF, Manassiev NA, Felton CV, et al. Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women. Clin Endocrinol (Oxf) 2004;60:541-549.
74. Hsia J, Bittner V, Tripputi M, et al. Metabolic syndrome and coronary angiographic disease progression: the Women's Angigraphic Vitamin and Estrogen trial. Am Heart J 2003;146:439-445.
75. Margolies KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 2004;47:1175-1187.
76. Howard BV, Hsia J, Ouyang P, et al. Postmenopausal hormone therapy is associated with atherosclerotic progression in women with abnormal glucose tolerance. Circulation 2004;110:201-206.